Prospective validation of a risk calculator which calculates the probability of a positive prostate biopsy in a contemporary clinical cohort

The ERSPC RC performs well in a Dutch clinical cohort in men with previous PSA tests and contemporary biopsy schemes, and outperforms a PSA and DRE-based approach in the decision to perform a biopsy.